Detection of Biochemically Recurrent Prostate Cancer with [18F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen Parameters
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Global Burden of Disease Cancer Collaboration; Fitzmaurice, C.; Allen, C.; Barber, R.M.; Barregard, L.; Bhutta, Z.A.; Brenner, H.; Dicker, D.J.; Chimed-Orchir, O.; Dandona, R.; et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017, 3, 524–548. [Google Scholar] [PubMed] [Green Version]
- Cookson, M.S.; Aus, G.; Burnett, A.L.; Canby-Hagino, E.D.; D’Amico, A.V.; Dmochowski, R.R.; Eton, D.T.; Forman, J.D.; Goldenberg, S.L.; Hernandez, J.; et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J. Urol. 2007, 177, 540–545. [Google Scholar] [PubMed]
- Roach, M., 3rd; Hanks, G.; Thames, H., Jr.; Schellhammer, P.; Shipley, W.U.; Sokol, G.H.; Sandler, H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 2006, 65, 965–974. [Google Scholar] [CrossRef] [PubMed]
- Jani, A.B.; Schreibmann, E.; Goyal, S.; Halkar, R.; Hershatter, B.; Rossi, P.J.; Shelton, J.W.; Patel, P.R.; Xu, K.M.; Goodman, M.; et al. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): A single centre, open-label, phase 2/3 randomised controlled trial. Lancet 2021, 397, 1895–1904. [Google Scholar] [CrossRef] [PubMed]
- Calais, J.; Armstrong, W.R.; Kishan, A.U.; Booker, K.M.; Hope, T.A.; Fendler, W.P.; Elashoff, D.; Nickols, N.G.; Czernin, J. Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. Eur. Urol. Focus 2021, 7, 238–240. [Google Scholar] [CrossRef] [PubMed]
- Calais, J.; Zhu, S.; Hirmas, N.; Eiber, M.; Hadaschik, B.; Stuschke, M.; Herrmann, K.; Czernin, J.; Kishan, A.U.; Nickols, N.G.; et al. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol. BMC Cancer 2021, 21, 512. [Google Scholar] [CrossRef]
- Wright, G.L., Jr.; Haley, C.; Beckett, M.L.; Schellhammer, P.F. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol. 1995, 1, 18–28. [Google Scholar] [CrossRef]
- Jones, W.; Griffiths, K.; Barata, P.C.; Paller, C.J. PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. Cancers 2020, 12, 1367. [Google Scholar] [CrossRef]
- Gorin, M.A.; Pomper, M.G.; Rowe, S.P. PSMA-targeted imaging of prostate cancer: The best is yet to come. BJU Int. 2016, 117, 715–716. [Google Scholar] [CrossRef] [Green Version]
- Sun, J.; Lin, Y.; Wei, X.; Ouyang, J.; Huang, Y.; Ling, Z. Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis. Front. Oncol. 2021, 11, 649171. [Google Scholar] [CrossRef]
- Morris, M.J.; Rowe, S.P.; Gorin, M.A.; Saperstein, L.; Pouliot, F.; Josephson, D.; Wong, J.Y.C.; Pantel, A.R.; Cho, S.Y.; Gage, K.L.; et al. Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clin. Cancer Res. 2021, 27, 3674–3682. [Google Scholar] [CrossRef]
- Mena, E.; Rowe, S.P.; Shih, J.H.; Lindenberg, L.; Turkbey, B.; Fourquet, A.; Lin, F.I.; Adler, S.; Eclarinal, P.; McKinney, Y.L.; et al. Predictors of 18F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy. J. Nucl. Med. 2022, 63, 1184–1190. [Google Scholar] [CrossRef] [PubMed]
- Ulaner, G.A.; Thomsen, B.; Bassett, J.; Torrey, R.; Cox, C.; Lin, K.; Patel, T.; Techasith, T.; Mauguen, A.; Rowe, S.P.; et al. 18F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation. Radiology 2022, 305, 419–428. [Google Scholar] [CrossRef]
- Balduzzi, S.; Rucker, G.; Schwarzer, G. How to perform a meta-analysis with R: A practical tutorial. Evid. Based Ment. Health 2019, 22, 153–160. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Markowski, M.C.; Sedhom, R.; Fu, W.; Gray, J.C.R.; Eisenberger, M.A.; Pomper, M.G.; Pienta, K.J.; Gorin, M.A.; Rowe, S.P. Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. J. Urol. 2020, 204, 496–502. [Google Scholar] [CrossRef] [PubMed]
- Song, H.; Harrison, C.; Duan, H.; Guja, K.; Hatami, N.; Franc, B.L.; Moradi, F.; Aparici, C.M.; Davidzon, G.A.; Iagaru, A. Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management. J. Nucl. Med. 2020, 61, 546–551. [Google Scholar] [CrossRef]
- Whiting, P.F.; Rutjes, A.W.; Westwood, M.E.; Mallett, S.; Deeks, J.J.; Reitsma, J.B.; Leeflang, M.M.G.; Sterne, J.A.C.; Bossuyt, P.M.M.; QUADAS-2 Group. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 2011, 155, 529–536. [Google Scholar] [CrossRef]
- Mena, E.; Lindenberg, M.L.; Turkbey, I.B.; Shih, J.H.; Harmon, S.A.; Lim, I.; Lin, F.; Adler, S.; Eclarinal, P.; McKinney, Y.L.; et al. 18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy. J. Nucl. Med. 2020, 61, 881–889. [Google Scholar] [CrossRef]
- Baratto, L.; Song, H.; Duan, H.; Hatami, N.; Bagshaw, H.P.; Buyyounouski, M.; Hancock, S.; Shah, S.; Srinivas, S.; Swift, P.; et al. PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. J. Nucl. Med. 2021, 62, 1545–1549. [Google Scholar] [CrossRef]
- Chausse, G.; Ben-Ezra, N.; Stoopler, M.; Levett, J.Y.; Niazi, T.; Anidjar, M.; Abikhzer, G.; Probst, S. Diagnostic performance of 18F-DCFPyL positron emission tomography/computed tomography for biochemically recurrent prostate cancer and change-of-management analysis. Can. Urol. Assoc. J. 2021, 15, 173–178. [Google Scholar] [CrossRef]
- Koschel, S.; Taubman, K.; Sutherland, T.; Yap, K.; Chao, M.; Guerrieri, M.; Benson, A.; Starmans, M.; Byrne, G.; Ong, G.; et al. Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: A prospective trial. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 3712–3722. [Google Scholar] [CrossRef] [PubMed]
- Luiting, H.B.; Remmers, S.; Meijer, D.; Vis, A.N.; Donswijk, M.; Oprea-Lager, D.E.; Emmett, L.; Rauscher, I.; Van der Poel, H.G.; Roobol, M.J.; et al. External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible? Eur. Urol. Open Sci. 2021, 28, 47–51. [Google Scholar] [CrossRef] [PubMed]
- Meijer, D.; van Leeuwen, P.J.; Oosterholt, P.M.J.; Bodar, Y.J.L.; van der Poel, H.G.; Hendrikse, N.H.; Donswijk, M.L.; Wondergem, M.; Vellekoop, A.E.; van Moorselaar, R.J.A.; et al. Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: A multicenter retrospective study. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 2960–2969. [Google Scholar] [CrossRef] [PubMed]
- Metser, U.; Ortega, C.; Hussey, D.; Chan, R.; Berlin, A.; Finelli, A.; Veit-Haibach, P. 18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center. Curr. Oncol. 2021, 28, 3251–3258. [Google Scholar] [CrossRef]
- Ortega, C.; Schaefferkoetter, J.; Veit-Haibach, P.; Anconina, R.; Berlin, A.; Perlis, N.; Metser, U. 18F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria. J. Nucl. Med. 2020, 61, 1615–1620. [Google Scholar] [CrossRef] [PubMed]
- Perry, E.; Talwar, A.; Taubman, K.; Ng, M.; Wong, L.M.; Booth, R.; Sutherland, T.R. [18F]DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA < 0.5 ng/mL. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 2038–2046. [Google Scholar]
- Rousseau, E.; Wilson, D.; Lacroix-Poisson, F.; Krauze, A.; Chi, K.; Gleave, M.; McKenzie, M.; Tyldesley, S.; Goldenberg, S.L.; Benard, F. A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer. J. Nucl. Med. 2019, 60, 1587–1593. [Google Scholar] [CrossRef] [Green Version]
- Rowe, S.P.; Campbell, S.P.; Mana-Ay, M.; Szabo, Z.; Allaf, M.E.; Pienta, K.J.; Pomper, M.G.; Ross, A.E.; Gorin, M.A. Prospective Evaluation of PSMA-Targeted 18F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer. J. Nucl. Med. 2020, 61, 58–61. [Google Scholar] [CrossRef]
- Wondergem, M.; Jansen, B.H.E.; van der Zant, F.M.; van der Sluis, T.M.; Knol, R.J.J.; van Kalmthout, L.W.M.; Hoekstra, O.S.; van Moorselaar, R.J.A.; Oprea-Lager, D.E.; Vis, A.N. Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 1911–1918. [Google Scholar] [CrossRef] [Green Version]
Author, Year | Radiotracer Dose | Time Interval between Injection and Scanning | PSA | Standard of Truth | # Patients |
---|---|---|---|---|---|
Baratto, 2021 [19] | 270.1 to 366.3 MBq (333 ± 25.9 MBq) | 60 to 120 min (81.2 ± 17 min) | Mean 5 ng/mL | At least part of the data was validated by histopathology | 28 |
Chaussé, 2021 [20] | 9 ± 1 mCi (333 ± 37 MBq) | 60–90 min | Median 2.27 ng/mL | At least part of the data was validated by histopathology | 93 |
Koschel, 2021 [21] | 250 MBq ± 50 MBq | 120 min | Median 0.32 ng/mL | No histopathologic validation | 98 |
Luiting, 2021 [22] | Not provided | Not provided | Median 0.30 ng/mL (IQR 0.23–0.70) | No histopathologic validation | 157 |
Markowski, 2020 [15] | 333 MBq (9 mCi) | 60 min | Median 0.7 ng/mL (IQR 0.3–1.8) | No histopathologic validation | 108 |
Meijer, 2021 [23] | 311 MBq (interquartile range (IQR) 301–322 MBq) | 120 min | The median PSA level at the time of the PET scan post-RARP was 0.5 ng/mL (IQR 0.2–1.1), median 0.9 ng/mL (IQR 0.3–2.8) in patients post-RARP + SRT, and median 2.8 ng/mL (IQR 1.3–5.6) in patients post-EBRT | No histopathologic validation | 253 |
Mena, 2020 [18] | Mean 299.9 ± 15.5 MBq, 8.09 mCi (6.2–8.8 mCi) | - | Median 2.5 ng/mL (range 0.21–35.5) | At least part of the data was validated by histopathology | 90 |
Mena, 2022 [12] | Mean 296 ± 33.3 MBq [8.0 ± 0.9 mCi]; range, 207.2–325.6 MBq (5.6–8.8 mCi) | 1–2 h | Median 1.6 ng/mL (range, 0.2–35.5) | No histopathologic validation | 245 |
Metser, 2021 [24] | 327 (±16.7) | 110.2 (±13.9) min | Median 3.0 mg/mL (range 0.5–43.3) | At least part of the data was validated by histopathology | 35 |
Morris, 2021 [11] | MBq median 349 range (277–410), mCi 9.42 (7.49–11.07) | median 79 range (59–115) | Median 0.8 ng/mL | At least part of the data was validated by histopathology | 208 |
Ortega, 2020 [25] | 335.5 MBq (range, 223–376 MBq) | approximately 120 min (mean, 115.1 min; range, 83–168 min) | Median 3.69 mg/L (range, 0.55–49.9 mg/L) | No histopathologic validation | 142 |
Perry, 2021 [26] | 250 MBq (±50 MBq | 120 min (±10 min) | Median 0.51 ng/mL (range, 0.08–58.9) | No histopathologic validation | 222 |
Rousseau, 2019 [27] | The administered activity was scaled by body weight (range, 237–474 MBq), allowing a 10% variation in target activity. | 120 min | Mean ± SD 5.20 ng/mL ± 6.50 | No histopathologic validation | 130 |
Rowe, 2020 [28] | 333 MBq (9 mCi) | 60 min | Median 0.4 ng/mL (range, 0.2–28.3) | No histopathologic validation | 31 |
Song, 2019 [16] | Mean 338.8 ± 25.3 | 60 min | Median 3.0 ng/mL (range, 0.23 to 698.4 ng/mL) | At least part of the data was validated by histopathology | 72 |
Ulaner, 2022 [13] | 333 MBq (9 mCi) ± 10% | 60 min | Median 0.7 ng/mL (range, 0.2–38.9 | All data was validated by histopathology | 92 |
Wondergem, 2019 [29] | 311 MBq | 120 min | _ | No histopathologic validation | 248 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sadaghiani, M.S.; Sheikhbahaei, S.; Al-Zaghal, A.; Solnes, L.B.; Pomper, M.G.; Oldan, J.D.; Ulaner, G.A.; Gorin, M.A.; Rowe, S.P. Detection of Biochemically Recurrent Prostate Cancer with [18F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen Parameters. Tomography 2023, 9, 1504-1514. https://doi.org/10.3390/tomography9040120
Sadaghiani MS, Sheikhbahaei S, Al-Zaghal A, Solnes LB, Pomper MG, Oldan JD, Ulaner GA, Gorin MA, Rowe SP. Detection of Biochemically Recurrent Prostate Cancer with [18F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen Parameters. Tomography. 2023; 9(4):1504-1514. https://doi.org/10.3390/tomography9040120
Chicago/Turabian StyleSadaghiani, Mohammad S., Sara Sheikhbahaei, Abdullah Al-Zaghal, Lilja B. Solnes, Martin G. Pomper, Jorge D. Oldan, Gary A. Ulaner, Michael A. Gorin, and Steven P. Rowe. 2023. "Detection of Biochemically Recurrent Prostate Cancer with [18F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen Parameters" Tomography 9, no. 4: 1504-1514. https://doi.org/10.3390/tomography9040120